Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?

Basit Öğe Kaydı
dc.authoridduran, Ayse Ocak/0000-0002-1703-726X
dc.authoridUysal, Mukremin/0000-0002-8524-0665
dc.authoriduçar, Mahmut/0000-0002-3311-6152
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridDuzkopru, Yakup/0000-0003-2314-5870
dc.authoridKaplan, Muhammet Ali/0000-0003-0882-0524
dc.authorwosidduran, Ayse Ocak/ABA-7090-2021
dc.authorwosidBerk, Veli/IXE-0017-2023
dc.authorwosidUysal, Mukremin/B-8956-2014
dc.authorwosiduçar, Mahmut/KBQ-8934-2024
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidDuzkopru, Yakup/GLT-1944-2022
dc.authorwosidÖZASLAN, ERSİN/V-3556-2017
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorKaraca, Halit
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorDuzkopru, Yakup
dc.contributor.authorUysal, Mukremin
dc.contributor.authorBerk, Veli
dc.date.accessioned2024-06-12T11:03:38Z
dc.date.available2024-06-12T11:03:38Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: The main goal of this study was to examine whether the occurrence of hypothyroidism during sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC) is associated with a better outcome. Methods: The study enrolled 81 patients with pathologically proven mRCC who were treated with sunitinib between March 2008 and June 2013. Thyroid function evaluation comprised (free-thyroxine) FT4 and thyroid-stimulating hormone (TSH) before treatment and at day 1 of each 6-week cycle. Survival analysis was performed using the Kaplan-Meier method, and the differences among the groups were determined using the log-rank test. Results: Hypothyroidism occurred in 30 (37%) of 81 patients within a median 3 months (range 1-18) of treatment initiation. There was a statistically significant correlation between the occurrence of hypothyroidism during treatment and the rate of objective remission (ORR) (hypothyroid patients vs euthyroid patients: 46.7 vs 13.7%, respectively; P = 0.001). Median progression-free survival (PFS) was 10 (95% CI 6.13-13.8) months in the euthyroid patients, and 17 (95% CI 9.33-24.6) months in the hypothyroid patients (P = 0.001). The median overall survival (OS) was 39 (95% CI 25.4-52.5) months in the hypothyroid patients and 20 (95% CI 14.7-25.2) months in the euthyroid patients (P = 0.019). Conclusions: The occurrence of hypothyroidism during treatment in patients was significantly associated with longer PFS, OS and better ORR in the current study.en_US
dc.identifier.doi10.1179/1973947815Y.0000000039
dc.identifier.endpage234en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue3en_US
dc.identifier.pmid25948423en_US
dc.identifier.scopus2-s2.0-84978701682en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage230en_US
dc.identifier.urihttps://doi.org/10.1179/1973947815Y.0000000039
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21732
dc.identifier.volume28en_US
dc.identifier.wosWOS:000380283700015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal Of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHypothyroidismen_US
dc.subjectSunitiniben_US
dc.subjectPrognosisen_US
dc.subjectMetastatic Renal Cell Canceren_US
dc.subjectThyroid-Hormoneen_US
dc.subjectCancer-Patientsen_US
dc.subjectKinaseen_US
dc.titleIs sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu